

References

I-200

1. Aimovig (erenumab-aooe) injection for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 05/2021.
2. Ajovy (fremanezumab-vfrm) injection for subcutaneous use [package insert]. Teva Pharmaceuticals. North Wales, PA. Revised 06/2021.
3. Emgality (galcanezumab-gnlm) injection for subcutaneous use [package insert]. Eli Lilly and Co. Indianapolis, IN. Revised 12/2019.
4. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(1):1-211.
5. Draft Evidence Report: Calcitonin Gene-Related Peptide (CGRP) Inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. *ICER- Institute for Clinical and Economic Review*. April 11, 2018.
6. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1081-1100.
7. Tepper, S, Ashina, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurology*. 2017;16(6):425-434.
8. Goadsby, P J, Reuter, et al. A controlled trial of erenumab for episodic migraine. *New England Journal of Medicine*. 2017;377(22):2123-2132.
9. Micromedex®Solutions Compendia.2021. Erenumab-aooe.
10. Micromedex®Solutions Compendia.2021. Fremanezumab-vfrm.
11. Micromedex®Solutions Compendia.2021. Galcanezumab-gnlm.
12. Clinical Pharmacology Compendia [database online].2021.Tampa FL: Gold Standard, Inc. Erenumab-aooe.
13. Clinical Pharmacology Compendia [database online].2021.Tampa FL: Gold Standard, Inc. Fremanezumab-vfrm.
14. Clinical Pharmacology Compendia [database online].2021. Tampa FL: Gold Standard, Inc. Galcanezumab-gnlm.
15. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. *New England Journal of Medicine*. 2019;381:132-141.
16. The American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. *Headache*. 2019;1-18.
17. Belin AC, Ran C, Edvinsson L. Calcitonin gene-related peptide (CGRP) and cluster headache. *Brain Sciences*. 2020;10(30):1-16.
18. Deng H, Li GG, Nie H, Feng YY, Guo GY, Guo WL, Tang ZP. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. *BMC Neurol*. 2020;20(1):57-69.

19. Erenumab-aooe. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
20. Fremanezumab-vfrm. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
21. Galcanezumab-gnlm. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
22. Erenumab-aooe In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 15, 2019.
23. Fremanezumab-vfrm In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 10, 2021.
24. Galcanezumab-gnlm In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated November 4, 2019.
25. Hayes, Inc. Hayes Health Prognosis Overview. Erenumab (Aimovig). Lansdale, PA: Hayes, Inc.; August 2020.